Mosaic Variegated Aneuploidy Syndrome via the CEP57 Gene
Summary and Pricing 
Test Method
Exome Sequencing with CNV Detection
| Test Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
|---|---|---|---|---|---|
| 8149 | CEP57 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information. If the Sanger option is selected, CNV detection may be ordered through Test #600.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
The Sanger Sequencing method for this test is NY State approved.
For Sanger Sequencing click here.Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Mosaic Variegated Aneuploidy (MVA) syndrome is a rare disease generally characterized by prenatal growth retardation, microcephaly, mental retardation, central nervous system abnormalities, and cancer predisposition (García-Castillo et al. 2008; Callier et al. 2005). Cancers can include Wilms tumor, rhabdomyosarcoma and leukemia (Hanks et al. 2004). Additional features may include Rhizomelic shortening of the upper limbs, skull anomalies with conserved head circumference, and absence of tumor development (Pinson et al. 2014). However, only five patients have been reported thus far and genotype-phenotype correlations have not been fully delineated.
Genetics
MVA syndrome is generally considered a rare autosomal recessive disorder that can be caused by pathogenic variants in the BUB1B and CEP57 genes. The CEP57 gene encodes a centrosomal protein that interacts with proteins in the microtubule skeleton and is involved in intracellular trafficking (Emanuele and Stukenberg 2007). Individuals with MVA show chromosomal abnormalities. There does not appear to be preferential specific chromosome gains and losses, and thus trisomies and monosomies appear to be random (Hanks and Rahman 2005). Reported pathogenic variants in the CEP57 gene are homozygous or compound heterozygous nonsense, and small insertions and duplications (Snape et al. 2011; Pinson et al. 2014).
Clinical Sensitivity - Sequencing with CNV PGxome
Clinical sensitivity is unknown at this time since MVA syndrome is a rare disease and relatively few patients have been reported. Analytical sensitivity should be high as all reported causative mutations are detectable by sequencing (Human Gene Mutation Database).
Testing Strategy
This test provides full coverage of all coding exons of the CEP57 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
This test is useful for individuals who are suspected to have MVA syndrome, have increased cytogenetic aneuploidies and/or familial carrier testing. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.
This test is useful for individuals who are suspected to have MVA syndrome, have increased cytogenetic aneuploidies and/or familial carrier testing. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.
Gene
| Official Gene Symbol | OMIM ID |
|---|---|
| CEP57 | 607951 |
| Inheritance | Abbreviation |
|---|---|
| Autosomal Dominant | AD |
| Autosomal Recessive | AR |
| X-Linked | XL |
| Mitochondrial | MT |
Disease
| Name | Inheritance | OMIM ID |
|---|---|---|
| Mosaic Variegated Aneuploidy Syndrome 2 | AR | 614114 |
Citations
- Callier P, Faivre L, Cusin V, Marle N, Thauvin-Robinet C, Sandre D, Rousseau T, Sagot P, Lacombe E, Faber V, Mugneret F. 2005. Microcephaly is not mandatory for the diagnosis of mosaic variegated aneuploidy syndrome. American Journal of Medical Genetics Part A 137A: 204–207. PubMed ID: 16059936
- Emanuele MJ, Stukenberg PT. 2007. Xenopus Cep57 is a novel kinetochore component involved in microtubule attachment. Cell 130: 893–905. PubMed ID: 17803911
- García-Castillo H, Vásquez-Velásquez AI, Rivera H, Barros-Núñez P. 2008. Clinical and genetic heterogeneity in patients with mosaic variegated aneuploidy: delineation of clinical subtypes. Am. J. Med. Genet. A 146A: 1687–1695. PubMed ID: 18548531
- Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D, Kidd A, Méhes K, Nash R, Robin N, Shannon N, Tolmie J, Swansbury J, Irrthum A, Douglas J, Rahman N. 2004. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 36: 1159–1161. PubMed ID: 15475955
- Hanks S, Rahman, N. 2005. Aneuploidy-cancer predisposition syndromes: a new link between the mitotic spindle checkpoint and cancer. Cell Cycle 4: 225–227. PubMed ID: 15655355
- Human Gene Mutation Database (Bio-base).
- Pinson L, Mannini L, Willems M, Cucco F, Sirvent N, Frebourg T, Quarantotti V, Collet C, Schneider A, Sarda P, Geneviève D, Puechberty J, Lefort G, Musio A. 2014. CEP57 mutation in a girl with mosaic variegated aneuploidy syndrome. American Journal of Medical Genetics Part A 164: 177–181. PubMed ID: 24259107
- Snape K, Hanks S, Ruark E, Barros-Núñez P, Elliott A, Murray A, Lane AH, Shannon N, Callier P, Chitayat D, Clayton-Smith J, Fitzpatrick DR, Gisselsson D, Jacquemont S, Asakura-Hay K, Micale MA, Tolmie J, Turnpenny PD, Wright M, Douglas J, Rahman N. 2011. Mutations in CEP57 cause mosaic variegated aneuploidy syndrome. Nat. Genet. 43: 527–529. PubMed ID: 21552266
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
Loading...
×
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.